Update on antiretroviral therapy based on data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)

Research output: Contribution to journalArticle

Abstract

The 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007) took place in Los Angeles, California, on February 25-28, 2007. This scientifically focused meeting covered a variety of HIV-related topics, including molecular epidemiology, immunology, virology, pathogenesis and the treatment and prevention of HIV infection. This article summarizes important presentations related to antiretroviral therapy that were made at the meeting. Highlights included efavirenz-associated lipoatrophy, the antiHIV activity of entecavir and phase III results for two novel first-in-class antiretroviral agents: maraviroc and raltegravir.

Original languageEnglish (US)
Pages (from-to)469-476
Number of pages8
JournalDrugs of the Future
Volume32
Issue number5
StatePublished - May 2007

Fingerprint

efavirenz
Anti-Retroviral Agents
Virology
Molecular Epidemiology
Los Angeles
Allergy and Immunology
HIV Infections
HIV
Therapeutics
Raltegravir Potassium
entecavir
maraviroc

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

@article{1bf46a599b544ceaa9133c5f2de0679e,
title = "Update on antiretroviral therapy based on data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)",
abstract = "The 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007) took place in Los Angeles, California, on February 25-28, 2007. This scientifically focused meeting covered a variety of HIV-related topics, including molecular epidemiology, immunology, virology, pathogenesis and the treatment and prevention of HIV infection. This article summarizes important presentations related to antiretroviral therapy that were made at the meeting. Highlights included efavirenz-associated lipoatrophy, the antiHIV activity of entecavir and phase III results for two novel first-in-class antiretroviral agents: maraviroc and raltegravir.",
author = "Zelalem Temesgen",
year = "2007",
month = "5",
language = "English (US)",
volume = "32",
pages = "469--476",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Update on antiretroviral therapy based on data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)

AU - Temesgen, Zelalem

PY - 2007/5

Y1 - 2007/5

N2 - The 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007) took place in Los Angeles, California, on February 25-28, 2007. This scientifically focused meeting covered a variety of HIV-related topics, including molecular epidemiology, immunology, virology, pathogenesis and the treatment and prevention of HIV infection. This article summarizes important presentations related to antiretroviral therapy that were made at the meeting. Highlights included efavirenz-associated lipoatrophy, the antiHIV activity of entecavir and phase III results for two novel first-in-class antiretroviral agents: maraviroc and raltegravir.

AB - The 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007) took place in Los Angeles, California, on February 25-28, 2007. This scientifically focused meeting covered a variety of HIV-related topics, including molecular epidemiology, immunology, virology, pathogenesis and the treatment and prevention of HIV infection. This article summarizes important presentations related to antiretroviral therapy that were made at the meeting. Highlights included efavirenz-associated lipoatrophy, the antiHIV activity of entecavir and phase III results for two novel first-in-class antiretroviral agents: maraviroc and raltegravir.

UR - http://www.scopus.com/inward/record.url?scp=34547800281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547800281&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 469

EP - 476

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 5

ER -